Document Type
Article
Publication Date
10-25-2024
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma characterized by distinct subtypes and heterogeneous treatment outcomes. Oxidative stress and the dysregulation of related regulatory genes are prevalent in DLBCL, prompting an investigation into the nuclear factor erythroid 2-related factor 2 (Nrf2)-kelch-like ECH-associated protein 1 (Keap1) signaling pathway and associated genes. The present study assessed pathological specimens and clinical data from 43 newly diagnosed patients with DLBCL, comparing the associations and correlations between the expression of Nrf2, Keap1, microtubule-associated protein 1 light chain 3β (LC3B) and nitrotyrosine and the activated B-cell (ABC) and germinal center B-cell (GCB) subtypes of DLBCL using immunohistochemistry and digital image analysis software. Nuclear Nrf2 activation was observed in 33.3% of patients with DLBCL ABC, demonstrating a higher prevalence of hepatitis B surface antigen positivity, calcium ions and significant body weight loss (P<0.05). Total Nrf2 expression was associated with the DLBCL GCB subtype and inversely correlated with Keap1 expression in the DLBCL ABC subtype. Furthermore, a positive correlation was demonstrated between Nrf2 and LC3, indicating that total Nrf2 is inhibited by Keap1 and regulates LC3 expression. The ABC subtype was also associated with lower white blood cell counts and more frequent chemotherapy courses than the GCB subtype. These findings suggest that nuclear Nrf2 could be a biomarker for DLBCL clinical diagnosis.
Recommended Citation
Hsu, Chin-Mu; Kao, Shih-Yu; Yen, Chia-Hung; Hsiao, Chi-En; Cho, Shih-Feng; Wang, Hui-Ching; Yeh, Tsung-Jang; Du, Jeng-Shiun; Wang, Min-Hong; Hsieh, Tzu-Yu; Hsiao, Samuel Yien; Tsai, Yuhsin; Hung, Li-Chuan; Liu, Yi-Chang; Chang, Kung-Chao; and Hsiao, Hui-Hua, "Biomarker Potential of Nuclear Nrf2 Activation in the ABC Subtype of Diffuse Large B‑cell Lymphoma" (2024). SKMC Student Presentations and Publications. Paper 29.
https://jdc.jefferson.edu/skmcstudentworks/29
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Language
English
Comments
This article is the author's final published version in Oncology Letters, Volume 29, Issue 1, October 2024, Article number 30.
The published version is available at https://doi.org/10.3892/ol.2024.14776.
Copyright © 2024 Hsu et al.